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The long and winding road-gene therapy for glioma
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Gene therapy approaches for glioblastoma multiforme (GBM) have been under investigation in clinical trials since the 1990s, but the results to date have been disappointing. A recently published phase III trial of adenovirus-based gene therapy for GBM has demonstrated modest-but possibly clinically relevant-improvements in patient survival. The latest study by Westphal et al. used a nonreplicating adenoviral vector express ing HSV1-tk (AdvHSVtk, also known as sitimagene ceradenovac). 3 In a previous phase I clinical trial, 4 GBM patients treated with AdvHSVtk had 80% increased sur vival (450 days) compared with those treated with either retroviral gene therapy (222 days) or controls (249 days). In an expanded phase II followup study, the same group compared 17 patients treated with AdvHSVtk with 19 patients ran domly assigned to receive control vectors. AdvHSVtk plus ganciclovir increased survival from 273 days to 494 days (80% improvement). 5 This work provided the impetus for the latest phase III trial. 3 The large multicentre phase III ASPECT trial commenced in 2005 and treated a total of 251 patients randomly allocated to sitima gene ceradenovec and ganciclovir gene therapy plus standard care, or to stand ard care alone. 3 Patients were recruited at 38 sites in nine different European countries. 119 experimental and 117 control patients could be evaluated at the end of the trial. The trial analysed a composite primary end point (time to death or re intervention) and overall survival. In patients allocated to gene therapy, the time to the primary end point increased by 40 days (308 days versus 268 days) compared with control values, and the median overall survival increased by 45 days (497 days versus 452 days).
Differences in radiotherapy, chemo therapy and surgery were unavoidable, as www.nature.com/nrneurol NEWS & VIEWS treatment could not be homogenized across the 38 centres. 3 In addition, temozo lomide was introduced as a GBM treatment while this trial was proceeding. As the use of this drug depended on approval and availability in each of the 38 centres, its administration was not universal. Patients were, therefore, treated by a large number of surgeons, and were administered different radiotherapy regimes and offered different chemotherapy options. In view of the lack of treatment standardization, our interpretation is that gene therapy was the main variable over a complex background of various surgical, radiotherapeutic and medical treatments. This complex patient-treatment scenario makes this trial closer to a trial testing new treatments in the general population, than to the more tightly controlled experimental settings of phase III trials.
How clinically significant are these find ings? The authors report statistical signifi cance for the primary end point, but not for overall survival (note, however, that absolute survival is comparable-40 days versus 45 days-for the primary and overall survival end points). These values were not considered convincing by the European Medicines Agency, 6 and this therapy is thus not currently available for the treatment of patients with GBM.
Given the published history, we can assume that the regulatory agencies and the trial investigators disagreed on the interpretation of the results. Two main chal lenges must be addressed when interpret ing the results of such trials. First, one must demon strate that criteria exist to determine whether a clinical trial of any phase and patient cohort size has failed and should not be pursued further. This scenario must be distinguished from noisy results that may obscure the existence of a responding subgroup of patients, or a small therapeu tic effect. We can determine beyond rea sonable doubt when a trial has failed. For example, the retroviral trial 2 provided suf ficient grounds to rule out further pursuit of nonreplicating retro viral therapy. However, we should not dis regard clinically relevant effects detected in small trials. 4, 5 Equally challenging is the interpreta tion of small differences seen in some large clinical trials. If the small differences rep resent real therapeutic benefits, we should certainly continue to either use or improve such therapies, as cumulative responses to combined treatments have been shown to provide the best survival rates in various cancers. Similarly, a patient who has sur vived a heart attack has an increased death risk, but treatment with several agents to simultaneously inhibit blood clot forma tion, block atrial fibrillation, block the renin-angiotensin axis and reduce hyper tension, and improve blood lipid patterns (statins), reduces the risk to preheart attack values. 7 As this example illustrates, small but effective and cumulative therapeutic effects can provide a treatment that is essentially 100% effective.
Westphal and colleagues [3] [4] [5] are to be commended for having followed Richard Dedekind's dictum and tested their poten tial therapy in the most stringent manner possible. Whether the treatment is effec tive but its effect size is small, or whether the treatment is ineffective, remains to be decided. In our opinion, the evidence sug gests that AdvHSVtk has a small but clini cally significant effect, and might be refined by further improvements in trial design, in combination with other approaches. Advantagene, Inc. (Auburndale, MA, USA) is preparing a phase III trial in the USA using AdvHSVtk (E. AguilarCordova, personal communication), indicating con tinued confidence in this approach. Equally, alternative gene therapy approaches for GBM, including replicating adenovirus, replicating retrovirus with conditional cytotoxicity, and replicating poliovirus, are producing suggestive results; 8 their ulti mate effectiveness will have to await large phase III randomized controlled trials. In addition, on the basis of promising pre clinical evidence, we are about to launch a phase I clinical trial that will combine AdvHSV1tk with an immunostimulatory cytokine expressed by an adenoviral vector, AdFlt3L (IND 14575). 9 In science (and medicine), what can be proven should not be believed without proof. Until we have proof of efficacy, we need time, resources to test the new therapies in stringent clinical trials, infinite stamina, and determination. We trust that conclusive clinical trial results will lead to prompt FDA approval to treat GBM patients.
